Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

Bulletin: ...FROST ADVISORY REMAINS IN EFFECT FROM 2 AM TO 9 AM EDT FRIDAY... * WHAT...Temperatures as low as 33 will result in frost formation. * WHERE...Portions of ...